☆ 4.7 Article

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Ivy Elizabeth Abraham et al.

Summary: Non-Hispanic Black and Hispanic patients with acute myeloid leukemia have higher mortality rates compared to non-Hispanic White patients, despite more favorable genetics and younger age. Structural racism and treatment patterns play significant roles in these survival disparities.

BLOOD (2022)

添加到收藏夹

Article Hematology

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

H. Moses Murdock et al.

Summary: Older patients with AML who undergo HCT have a high risk of relapse and poor survival. The outcomes of HCT in these patients are primarily driven by baseline genetic factors rather than mutations present in remission.

BLOOD (2022)

添加到收藏夹

Article Medicine, General & Internal

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Pau Montesinos et al.

Summary: This study demonstrated that the combination therapy of oral ivosidenib and azacitidine showed better event-free survival and longer overall survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Letter Hematology

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Sun Loo et al.

BLOOD (2022)

添加到收藏夹

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

添加到收藏夹

Article Oncology

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Daniel Bottomly et al.

Summary: This report presents findings from a large cohort of AML patients, combining genomic, transcriptomic, and clinical data to uncover associations between drug sensitivity, cell differentiation state, and patient survival prediction.

CANCER CELL (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Unified classification and risk-stratification in Acute Myeloid Leukemia

Yanis Tazi et al.

Summary: This study characterizes the genomic landscape of AML and identifies 16 molecular subgroups that have clinical relevance in disease classification and risk prognostication. The findings provide a unified framework for AML classification and risk stratification, and also offer a patient-tailored clinical decision support tool.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Review Oncology

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

Nicholas J. Short et al.

Summary: The study found that achieving MRD negativity in AML patients in complete remission is associated with improved DFS and OS outcomes, regardless of MRD threshold or analytic sensitivity.

LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Jesse M. Tettero et al.

Summary: Experts from the MRD Working Party of the European LeukemiaNet evaluated the key factors for accurate MFC-MRD measurement in acute myeloid leukemia (AML) and provided recommendations to ensure quality and reproducibility of results. The recommendations were tested by comparing two 8-color MRD panels in multiple laboratories, confirming their feasibility.

HEMASPHERE (2022)

添加到收藏夹

Article Hematology

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser et al.

Summary: The European LeukemiaNet MRD Working Party updated the 2018 MRD recommendations, including technical specifications and integrative assessments. They also proposed the use of MRD as a prognostic and surrogate endpoint for drug testing, as well as the clinical implications of MRD assessment in AML. Recommendations include technical requirements for flow cytometry and molecular MRD analysis, as well as reporting methods for MRD results.

BLOOD (2021)

添加到收藏夹

Article Biophysics

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Antonio M. Jimenez Jimenez et al.

Summary: The study established an adapted European LeukemiaNet (aELN) risk classification to predict post-transplant outcomes in adult AML patients, finding that patients in the adverse risk group had the highest risk of relapse and inferior disease-free and overall survival, highlighting the need for novel approaches to mitigate relapse in this high-risk group.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹

Letter Biophysics

Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation

Emily C. Liang et al.

Summary: Measurable residual disease is associated with poor prognosis in AML, and new NGS methods are highly sensitive in detecting MRD. The use of FLT3 inhibitors post-HCT is crucial for maintaining remission. Early post-HCT MRD negatively impacts PFS, while maintenance FLT3 inhibitors lead to superior PFS and OS for both MRD-negative and MRD-positive patients.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹

Article Oncology

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

Charles Craddock et al.

Summary: The intensified RIC conditioning regimen, FLAMSA-Bu, did not improve outcomes for adults undergoing transplantation for high-risk AML or MDS, regardless of pretransplant MRD status. Pretransplant detectable MRD was associated with disease relapse, but acquisition of full donor T-cell chimerism improved overall survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea et al.

Summary: The NCCN Guidelines for Acute Myeloid Leukemia provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment. Recent updates focus on familial genetic alterations, treatment strategies for low-risk and favorable-risk AML, venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Oncology

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

Bruno Paiva et al.

Summary: This study analyzed the role of decentralized assessment of MRD in AML patients and found that MFC-based MRD evaluation has prognostic significance, yet limited predictive value in models including other factors. Methodological, interpretation, and reporting aspects of MFC testing impact its ability to differentiate patients with different CIR, highlighting the need for greater standardization.

LEUKEMIA (2021)

添加到收藏夹

Article Medicine, General & Internal

Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers

Eric J. Duncavage et al.

Summary: This study showed that whole-genome sequencing provided rapid and accurate genomic profiling in patients with AML or MDS, with a greater diagnostic yield than conventional cytogenetic analysis, and more efficient risk stratification based on standard risk categories.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Education, Scientific Disciplines

Increasing access to allotransplants in the United States: the impact of race, geog ra phy, and socioeconomics

Sanghee Hong et al.

Summary: Allogeneic hematopoietic cell transplantation (HCT) is significantly influenced by racial, socioeconomic, and geographic disparities, with minority populations facing challenges in finding optimal donors and accessing transplant centers. Research has focused on social determinants of health affecting access to HCT, particularly race/ethnicity and socioeconomic status, with a pressing need for interventions to address these disparities. Additional studies are needed to explore opportunities for future research and policy changes to mitigate these disparities.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)

添加到收藏夹

Article Hematology

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

Richard Dillon et al.

BLOOD (2020)

添加到收藏夹

Article Oncology

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

Christopher S. Hourigan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)

Andreas Burchert et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis

Nicholas J. Short et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Hematology

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Zheng Zhou et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Gerrit J. Schuurhuis et al.

BLOOD (2018)

添加到收藏夹

Article Medicine, General & Internal

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

M. Jongen-Lavrencic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Hematology

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

Felicitas Thol et al.

BLOOD (2018)

添加到收藏夹

Article Oncology

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Functional genomic landscape of acute myeloid leukaemia

Jeffrey W. Tyner et al.

NATURE (2018)

添加到收藏夹

Article Hematology

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Mark J. Levis et al.

BLOOD ADVANCES (2018)

添加到收藏夹

Review Hematology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Doehner et al.

BLOOD (2017)

添加到收藏夹

Article Hematology

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

Sarah A. Buckley et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Review Oncology

Measurable residual disease testing in acute myeloid leukaemia

C. S. Hourigan et al.

LEUKEMIA (2017)

添加到收藏夹

Article Medicine, General & Internal

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

R. M. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Hematology

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

Sarah A. Buckley et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Article Hematology

Midostaurin approved for FLT3-mutated AML

Mark Levis

BLOOD (2017)

添加到收藏夹

Article Oncology

Untitled

CANCER (2016)

添加到收藏夹

Article Oncology

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Daisuke Araki et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Assessment of Minimal Residual Disease in Standard-Risk AML

A. Ivey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

Jeffery M. Klco et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

添加到收藏夹

Review Medicine, General & Internal

Acute Myeloid Leukemia

Hartmut Doehner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

J. J. Cornelissen et al.

LEUKEMIA (2015)

添加到收藏夹

Review Hematology

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

Boglarka Gyurkocza et al.

BLOOD (2014)

添加到收藏夹

Article Medicine, General & Internal

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Jay P. Patel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Review Medicine, General & Internal

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials

John Koreth et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)

添加到收藏夹

Article Hematology

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

ML Sorror et al.

BLOOD (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.